Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

BACKGROUND: This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. METHODS: 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Transl Med
Prif Awduron: Facchini, Gaetano, Rossetti, Sabrina, Berretta, Massimiliano, Cavaliere, Carla, Scagliarini, Sarah, Vitale, Maria Giuseppa, Ciccarese, Chiara, Di Lorenzo, Giuseppe, Palesandro, Erica, Conteduca, Vincenza, Basso, Umberto, Naglieri, Emanuele, Farnesi, Azzurra, Aieta, Michele, Borsellino, Nicolò, La Torre, Leonardo, Iovane, Gelsomina, Bonomi, Lucia, Gasparro, Donatello, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Lo Re, Giovanni, Grillone, Francesco, Marchetti, Paolo, De Vita, Ferdinando, Scavelli, Claudio, Sini, Claudio, Pisconti, Salvatore, Crispo, Anna, Gebbia, Vittorio, Maestri, Antonio, Galli, Luca, De Giorgi, Ugo, Iacovelli, Roberto, Buonerba, Carlo, Cartenì, Giacomo, D’Aniello, Carmine
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2019
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716812/
https://ncbi.nlm.nih.gov/pubmed/31464635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-2047-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg